LivaNova PLC Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.3%projected annual EPS growth
Analyst Coverage
10analysts covering
FY Revenue (est.)
$1.5Bnext fiscal year
FY EPS (est.)
$4.34next fiscal year
Monitoring Framework
Key Performance Indicators
Constant-Currency Revenue Growth Quarterly1,110.0%Target: 7.0% to 8.0% for FY 2026
Adjusted Diluted Earnings Per Share (EPS) Quarterly1.0Target: $4.20 to $4.30 for FY 2026
Cardiopulmonary Segment Revenue Growth (Constant-Currency) Quarterly1,400.0%
Watch Items
- FDA Supplement Review and Launch of Next-Generation MRI-Compatible OSA DeviceAction: Monitor FDA regulatory milestones and pre-commercialization activities for the aura6000 system.
- SNIA Environmental Liability ResolutionAction: Track legal proceedings, cash outflows, and potential adjustments to the estimated environmental liability.
Research as of 19 Jun 2026